Overview

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Veliparib